Photobiomodulation and visual stimulation against cognitive decline and Alzheimer's disease pathology: A systematic review

被引:13
|
作者
Monteiro, Francisca [1 ,2 ,3 ]
Carvalho, Oscar [1 ,3 ]
Sousa, Nuno [2 ,4 ]
Silva, Filipe S. [1 ,3 ]
Sotiropoulos, Ioannis [2 ,4 ,5 ]
机构
[1] Univ Minho, Ctr Microelectromechan Syst CMEMS, Campus Azurem, P-4800058 Guimaraes, Portugal
[2] ICVS 3Bs PT Govt Associate Lab, Braga, Portugal
[3] Univ Minho, Associate Lab, LABBELS, Guimaraes, Portugal
[4] Univ Minho, Life & Hlth Sci Res Inst ICVS, Sch Med, Campus Gualtar, P-4710057 Braga, Portugal
[5] NCSR Demokritos, Inst Biosci & Applicat, Athens, Greece
关键词
Alzheimer's disease; cognitive decline; light-based therapies; photobiomodulation; visual stimulation; LEVEL LASER THERAPY; TRANSCRANIAL LED THERAPY; MOUSE MODEL; CELL APOPTOSIS; LIGHT; BRAIN; PROPAGATION; DYSFUNCTION; RESPONSES; STRESS;
D O I
10.1002/trc2.12249
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
IntroductionGiven the ineffectiveness of the available drug treatment against Alzheimer disease (AD), light-based therapeutic modalities have been increasingly receiving attention with photobiomodulation (PBM) and, more recently, visual stimulation (VS) being among the most promising approaches. However, the PBM and VS light parameters tested so far, as well as their outcomes, vary a lot with conflicting results being reported. MethodsBased on Scopus, PubMed, and Web of Science databases search, this systematic review summarizes, compares, and discusses 43 cell, animal, and human studies of PBM and VS related to cognitive decline and AD pathology. ResultsPreclinical work suggests that PBM with 640 +/- 30-nm light and VS at 40 Hz attenuates A beta and Tau pathology and improves neuronal and synaptic plasticity with most studies pointing towards enhancement of degradation/clearance mechanisms in the brain of AD animal models. Despite the gap of the translational evidence for both modalities, the few human studies performed so far support the use of PBM at 810-870 nm light pulsing at 40 Hz for improving brain network connectivity and memory in older subjects and AD patients, while 40 Hz VS in humans seems to improve cognition; further clinical investigation is urgently required to clarify the beneficial impact of PBM and VS in AD patients. DiscussionThis review highlights PBM and VS as promising light-based therapeutic approaches against AD brain neuropathology and related cognitive decline, clarifying the most effective light parameters for further preclinical and clinical testing and use. HighlightsLight-based brain stimulation produces neural entrainment and reverts neuronal damageBrain PBM and VS attenuate AD neuropathologyPMB and VS are suggested to improve cognitive performance in AD patients and animal modelsLight stimulation represents a promising therapeutic strategy against neurodegeneration
引用
收藏
页数:24
相关论文
共 50 条
  • [21] Anxiety and depression in Alzheimer’s disease: a systematic review of pathogenetic mechanisms and relation to cognitive decline
    Rossana Botto
    Nicoletta Callai
    Aurora Cermelli
    Lorenzo Causarano
    Innocenzo Rainero
    Neurological Sciences, 2022, 43 : 4107 - 4124
  • [22] Plasma S100β is a predictor for pathology and cognitive decline in Alzheimer's disease
    Nehra, Geetika
    Maloney, Bryan J.
    Smith, Rebecca R.
    Chumboatong, Wijitra
    Abner, Erin L.
    Nelson, Peter T.
    Bauer, Bjorn
    Hartz, Anika M. S.
    FLUIDS AND BARRIERS OF THE CNS, 2025, 22 (01):
  • [23] Association Between Vascular Pathology and Rate of Cognitive Decline Independent of Alzheimer's Disease Pathology
    Ezzati, Ali
    Wang, Cuiling
    Lipton, Richard B.
    Altschul, Dorothea
    Katz, Mindy J.
    Dickson, Dennis W.
    Derby, Carol A.
    JOURNAL OF THE AMERICAN GERIATRICS SOCIETY, 2017, 65 (08) : 1836 - 1841
  • [24] Olfaction as a Predictor of Cognitive Decline and Alzheimer's Disease Pathology in Old Age
    Knight, J.
    Piccinin, A.
    GERONTOLOGIST, 2016, 56
  • [25] Deep Brain Stimulation as an Emerging Therapy for Cognitive Decline in Alzheimer Disease: Systematic Review of Evidence and Current Targets
    Picton, Bryce
    Wong, Joey
    Lopez, Alexander M.
    Solomon, Sean S.
    Andalib, Saman
    Brown, Nolan J.
    Dutta, Rajeev R.
    Paff, Michelle R.
    Hsu, Frank P.
    Oh, Michael Y.
    WORLD NEUROSURGERY, 2024, 184 : 253 - 266.e2
  • [26] Antibodies against β-amyloid slow cognitive decline in Alzheimer's disease
    Hock, C
    Konietzko, U
    Streffer, JR
    Tracy, J
    Signorell, A
    Müller-Tillmanns, B
    Lemke, U
    Henke, K
    Moritz, E
    Garcia, E
    Wollmer, MA
    Umbricht, D
    de Quervain, DJF
    Hofmann, M
    Maddalena, A
    Papassotiropoulos, A
    Nitsch, RM
    NEURON, 2003, 38 (04) : 547 - 554
  • [27] Hypertension and Alzheimer's disease pathology at autopsy: A systematic review
    Abdulrahman, Herrer
    van Dalen, Jan Willem
    den Brok, Melina
    Latimer, Caitlin S.
    Larson, Eric B.
    Richard, Edo
    ALZHEIMERS & DEMENTIA, 2022, 18 (11) : 2308 - 2326
  • [28] Neuroimaging Predictors of Cognitive Resilience against Alzheimer's Disease Pathology
    Williams, McKenna E.
    Fennema-Notestine, Christine
    Bell, Tyler R.
    Lin, Shu-Ju
    Glatt, Stephen J.
    Kremen, William S.
    Elman, Jeremy A.
    Alzheimers Dis Neuroimaging Initiative
    ANNALS OF NEUROLOGY, 2025,
  • [29] Transcranial magnetic stimulation predicts cognitive decline in patients with Alzheimer's disease
    Motta, Caterina
    Di Lorenzo, Francesco
    Ponzo, Viviana
    Pellicciari, Maria Concetta
    Bonni, Sonia
    Picazio, Silvia
    Mercuri, Nicola Biagio
    Caltagirone, Carlo
    Martorana, Alessandro
    Koch, Giacomo
    JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 2018, 89 (12): : 1237 - 1242
  • [30] Effects of Diabetes Mellitus on Cognitive Decline in Patients with Alzheimer Disease: A Systematic Review
    Li, Jun
    Cesari, Matteo
    Liu, Fei
    Dong, Birong
    Vellas, Bruno
    CANADIAN JOURNAL OF DIABETES, 2017, 41 (01) : 114 - 119